ABSTRACT

This study conducts a detailed pharmaceutical and pharmacological evaluation of Nishamalaki Capsule, a phytomedicinal preparation composed of Curcuma longa (turmeric) and Emblica officinalis (amla). The research emphasizes formulation standardization through comprehensive physicochemical and microbial analyses, performed in adherence to both Ayurvedic Pharmacopoeia of India (API) and contemporary quality control norms. Analytical results confirmed optimal parameters: moisture content (6.245%), total ash (5.034%), acid-insoluble ash (0.641%), water-soluble extractive (30.434%), and alcohol-soluble extractive (22.346%), alongside a rapid disintegration time of 10 minutes and the absence of specified microbialcontaminants. Pharmacological assessment underscores the formulation’s multi-target potential in Type 2 Diabetes Mellitus, driven by synergistic bioactive compounds including curcuminoids and emblicanin derivatives. These constituents are documented to enhance insulin sensitivity, mitigate oxidative stress, modulate inflammatory pathways, and improve lipid profiles. The study confirms the formulation’s compliance with quality benchmarks, reinforcing its reliability and therapeutic promise in the integrative management of diabetes and associated metabolic dysfunctions. Further robust clinical trials are recommended to validate its efficacy and long-term safety. Keywords: Nishamalaki Capsule, Diabetes Mellitus, Standardization, Phytoconstituents, Metabolic Regulation
Publication date: 2026/10/01

https://www.ijbpas.com/pdf/2026/October/MS_IJBPAS_2026_10503.pdf

Download PDF
doi.org/10.31032/IJBPAS/2026/15.10.10503